Similar Items: Association of autoimmune diseases with biologic agents targeting type 2 immunity: An observational study using a claims database
- Balancing the complex interplay between type 2 immunity‐targeting biologics and autoimmune phenomena in real‐world practice
- Management of interstitial lung disease in systemic autoimmune rheumatic diseases: a survey of rheumatologists and pulmonologists
- Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis
- Epstein‐Barr virus as a driver of lupus: Rethinking triggers in autoimmunity
- Type I interferon overactivation in sera of patients with anti‐MDA5‐positive dermatomyositis‐associated interstitial lung disease
- From Nerve to Autoimmunity: Acute Guillain-Barré Syndrome in a 4-Year-Old with Early-Onset Pediatric Systemic Lupus Erythematosus